Encore Medical is a medical device company that manufactures and sells septal occlusion devices, which are implantable devices designed to close structural defects in the heart. The company's primary product is a patent foramen ovale (PFO) closure device, used to reduce the risk of recurrent cryptogenic strokes. Encore also offers atrial septal defect (ASD) closure devices. Both products are delivered through a catheter in a cardiac catheterization lab, avoiding open-heart surgery and eliminating the need for lifelong blood-thinning medication. Encore manufactures all of its products in-house at a facility in Minnesota. The company's business model relies on selling devices to independent distributors, who resell them to hospitals and clinics. Encore currently operates exclusively outside the United States, distributing across approximately 20 countries in Europe, Latin America, and the Middle East. The company's near-term growth strategy focuses on completing clinical trials to secure FDA approval and enter the U.S. market.